Keros Therapeutics, Inc. $KROS Shares Purchased by Goldman Sachs Group Inc.

Key Points

• Goldman Sachs Group Inc. increased its stake in Keros Therapeutics by 38.3%, now owning approximately 1.82% of the company, valued at $7.55 million.
• Keros Therapeutics has received mixed ratings from analysts, with some maintaining a "buy" rating and others downgrading their price targets significantly.
• Despite posting a quarterly revenue of only $0.02 million, Keros reported a 49,002.7% year-over-year revenue increase, alongside earnings per share surpassing analysts' expectations.

Goldman Sachs Group Inc. increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 38.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 740,606 shares of the company's stock after purchasing an additional 205,022 shares during the period. Goldman Sachs Group Inc. owned 1.82% of Keros Therapeutics worth $7,547,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Keros Therapeutics by 31.1% during the 1st quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company's stock valued at $26,151,000 after acquiring an additional 609,212 shares during the period. ADAR1 Capital Management LLC grew its holdings in shares of Keros Therapeutics by 6,294.5% during the first quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company's stock worth $15,147,000 after buying an additional 1,463,215 shares in the last quarter. Federated Hermes Inc. grew its holdings in shares of Keros Therapeutics by 882.3% during the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company's stock worth $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Millennium Management LLC boosted its position in shares of Keros Therapeutics by 53.3% during the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after acquiring an additional 305,169 shares during the last quarter. Finally, DRW Securities LLC acquired a new position in shares of Keros Therapeutics during the 1st quarter valued at about $4,737,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Keros Therapeutics Stock Up 1.6%

Keros Therapeutics stock traded up $0.25 during mid-day trading on Tuesday, hitting $15.80. The company had a trading volume of 480,977 shares, compared to its average volume of 422,590. The stock has a market cap of $641.80 million, a price-to-earnings ratio of 50.97, a PEG ratio of 2.00 and a beta of 1.06. Keros Therapeutics, Inc. has a 1 year low of $9.12 and a 1 year high of $72.37. The business has a fifty day moving average of $14.70 and a 200 day moving average of $13.56.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($1.14) by $0.38. Keros Therapeutics had a return on equity of 2.96% and a net margin of 8.06%.The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $3.83 million. During the same period last year, the company earned ($1.25) earnings per share. The company's revenue for the quarter was up 49002.7% on a year-over-year basis. Equities analysts anticipate that Keros Therapeutics, Inc. will post -4.74 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on KROS shares. Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Finally, HC Wainwright lowered their price target on shares of Keros Therapeutics from $25.00 to $20.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Seven research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.00.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.